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Abstract 
Purpose: To evaluate clinical results of catheter-based interstitial high-dose-rate (HDR) brachytherapy (BT) as ad-
juvant treatment in previously irradiated recurrent breast cancer.
Material and methods: Between January 2011 and September 2015, 31 consecutive patients with histologically 
confirmed recurrent breast cancer after conservative surgery and conventional whole breast radiotherapy, were re-
treated with a second conservative surgical resection and reirradiated with adjuvant interstitial HDR-BT. None of 
the brachytherapy implant was performed during the quadrantectomy procedure. A dose of 34 Gy in 10 fractions, 
2 fractions per day, with a minimal interval of 6 hours was delivered.
Results: At the time of the implant, the median age of patients was 59.7 years (range, 39.3-74.9 years). The median 
time from first treatment until BT for local recurrence was 11.9 years (range, 2.5-27.8 years). The median interval be-
tween salvage surgery and BT was 3.6 months (range, 1-8.2 months). No acute epidermitis or soft tissue side effects 
higher than grade 2 were recorded, with good cosmetic results in all patients. Most of the patients presented grade 
1-2 late side effects. Only one patient developed grade 3 liponecrosis. After a median follow-up of 73.7 months (range, 
28.8-102.4 months), the overall survival and cancer specific survival were 87.1% and 90.3%, respectively; 5-year local 
control and 5-year progression-free survival rate were 90.3% and 83.9%, respectively.
Conclusions: Our preliminary analysis showed that HDR-BT is a feasible treatment for partial breast reirradiation 
offering very low complications rate and fast procedure. Higher patients’ cohort is warranted in order to define the role 
of this treatment modality in the breast conservative management of local recurrence. 
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Purpose 
Locally recurrent breast cancer after conservative sur-
gery and adjuvant whole-breast external beam radiother-
apy (EBRT) is an uncommon event, which historically has 
been reported in around 6% in node-negative patients (or 
less, as in the control arm of ELIOT – intraoperative ra-
diotherapy with electrons trial) and in 10% in node-posi-
tive patients at 5 years, or even lower in more recent trials 
[1,2]. Studies of the patterns of failure after conservative 
approach demonstrated that the same quadrant as the 
primary tumor is most frequently affected by an ipsilat-
eral breast tumor recurrence (IBTR). Whatever it is seen 
as a true relapse or as a new tumor, the standard of care 
is mastectomy, with or without post-operative reirradia-
tion, which ensure a local control of 68-98%. Alternative 
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approaches are under investigation [3,4,5,6,7,8,9]. Ac-
cording to a recent review, after a second breast conserv-
ing surgery (SBCS) alone, the weighted rates for 5-year 
local control, distant metastasis-free survival, and overall 
survival were 76%, 73%, and 77%, respectively [10]. 
At our institute, after a SBCS approach, recurrent 
tumor size ≤ 2 cm, Ki-67 < 20%, and time to relapse 
> 48 months were associated with an increased disease- 
free survival, whereas absence of estrogen receptors af-
fected overall survival [11,12]. 
The addition of a further course of adjuvant radiother-
apy after SBCS might reduce the risk of local recurrence, 
and some recent guidelines have strongly suggested to 
consider the conservative approach including reirradia-
tion along with salvage mastectomy. The possibility of 
an early diagnosis and the availability of high precision 
EBRT techniques offered by current technological ad-
vances has paved the way for salvage breast conservation 
based on wide local excision partial breast reirradiation 
[13,14,15,16,17,18,19,20,21,22,23,24,25]. 
The conservative approach can be proposed after 
careful evaluation of surgical feasibility, which must 
consider the IBTR dimension, size, focality, and the 
breast size in order to achieve cosmetically acceptable 
results. Several authors have described the use of ad-
juvant breast reirradiation with brachytherapy (BT) 
[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40], intraoper-
ative radiation therapy (IORT) [41,42,43,44,45,46], pro-
ton beam radiotherapy [47,48], or EBRT with or without 
concurrent hyperthermia to increase local control rate 
[49,50,51,52,53,54]. 
Brachytherapy can be delivered using low-dose-rate 
(LDR), pulsed-dose-rate (PDR), or high-dose-rate (HDR) 
modality. While with LDR technique irradiation is de-
livered continuously, with HDR and PDR BT the dose 
is given with a fractionation schedule using afterloading 
equipment [55]. 
The purpose of this study, called BALESTRA 
(Brachytherapy as Adjuvant Local rEirradiation for Sal-
vage Treatment of Recurrent breAst cancer), was to re-
port on acute and late toxicity and preliminary outcome 
of a single-institution experience of accelerated partial 
breast reirradiation with adjuvant interstitial HDR-BT. 
Material and methods 
Patient, tumor, and treatment characteristics 
The inclusion criteria were as follow: 1. Patients treat-
ed with a SBCS for ipsilateral unicentric in-breast-recur-
rence after conservative surgery and adjuvant whole-
breast EBRT; 2. Multidisciplinary tumor board to confirm 
the treatment strategy; 3. Written informed consent. In 
addition, patients gave consent for the use of their an-
onymized data for research and educational purposes. 
Patients’ evaluation included complete medical history 
and physical examination. For each patient, tumor (pri-
mary and recurrence) and treatment characteristics, such 
as histology, recurrence site, TNM classification [56], time 
interval between primary tumor and relapse, doses of 
EBRT, and BT implant features were collected. 
All the procedures were carried out using afterloading 
technique under local or general anesthesia. Stainless steel 
guide needles and/or vascular catheters were implanted 
through the skin, parallel to the chest wall and to each oth-
er, under ultrasound and manual control. Subsequently, 
polyethylene afterloading catheters were inserted through 
each needle into the tissue followed by removal of the 
needles themselves. All the catheters were secured using 
plastic buttons without skin sutures. Once the implantation 
was completed, a computed tomography (CT) scan with 
2.5 mm slice thickness and separation was performed and 
entered into BT treatment planning system (Oncentra 
Brachy Planning, Nucletron-Elekta) allowing reconstruc-
tion of the catheters, definition of the target volumes and 
of the nearby organs at risk. No patients received intrave-
nous contrast. The clinical target volume (CTV) included 
nearly 1-2 cm of healthy breast tissue around the tumor bed 
in all directions, with a distance between the implant and 
thoracic wall and/or skin of at least 5-7 mm [57,58,59,60]. 
Computerized optimization of dwell positions and times 
of stepping source was performed for fine tuning of isod-
ose distributions. Treatment was delivered using an HDR 
afterloader (MicroSelectron, Nucletron-Elekta), containing 
a single Iridum-192 (192Ir) source. Before every BT session, 
the implant was examined to ensure that there was no crit-
ical displacement of the catheters. A total dose of 34 Gy in 
10 fractions, 2 fractions per day, with a minimum interval of 
6 hours in-between was administrated. At the end of the last 
fraction, the implant catheters were removed. 
Endpoint analysis 
All patients were followed up every three to six 
months to analyze acute and late toxicity, according to 
the Radiation Therapy Oncology Group/European Orga-
nization for Research and Treatment of Cancer (RTOG/
EORTC) scoring system [61], local control, and survival. 
The median follow-up was calculated from the end of BT 
to the last clinical observation. Local control (LC), which 
was defined as the absence of disease in the breast after 
conservative salvage surgery and BT. Progression-free 
survival (PFS) was calculated from the salvage surgery to 
the time of local, nodal and/or distant relapse, or death 
due to breast cancer, whichever occurred first. Cancer 
specific survival (CSS) and overall survival (OS) were cal-
culated from the salvage surgery to the time of death due 
to breast cancer and death due to any cause, respectively. 
Cosmetic results were reported using the National 
Surgical Adjuvant Breast and Bowel Project (NSABP)/
RTOG breast cosmesis grading scale: excellent, good, fair, 
and poor [62].
Results
Between January 2011 and September 2015, 31 con-
secutive patients with histologically confirmed IBTR 
were treated with adjuvant interstitial HDR-BT. Patients, 
tumor, and treatments characteristics are listed in Table 1. 
Median age at first diagnosis was 46 years (range, 36.1-
61.4 years). Initial surgical treatment was quadrantec-
tomy and sentinel node biopsy with or without axillary 
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Table 1. Patients and tumor characteristics
Characteristics (n = 31 patients) Primary, n (%) IBTR, n (%) 
Age < 50 years 20 (65) 7 (23) 
50-60 years 9 (29) 9 (29) 
> 60 years 2 (6) 15 (48) 
Median (range) 46 years (range, 36.1-61.4) 59.7 years (range, 39.3-74.9) 
Time to IBTR 
(between first and second con-
servative surgery) 
< 5 years – 4 (13) 
5-10 years – 9 (29) 
> 10 years – 18 (58) 
Median (range) – 11.9 years (range, 2.5-27.8) 
IBTR site True marginal – 22 (71) 
Elsewhere – 9 (29) 
pT stage pTis 4 (13) 1 (3) 
pT1 16 (51) 28 (91) 
pT2 7 (23) 2 (6) 
Data not available 4 (13) –
pN status Positive 11 (35) 1 (3) 
Negative 14 (45) 11 (36) 
Data not available 6 (20) 19 (61) 
Stage 0 3 (10) 1 (3) 
I 13 (42) 26 (84) 
II 11 (35) 4 (13) 
Data not available 4 (13) –
Histological type Ductal invasive 18 (58) 21 (68) 
Lobular invasive 6 (20) 6 (20) 
Ductal and lobular 1 (3) –
In situ 3 (10) 1 (3) 
Other 2 (6) 2 (6) 
Data not available 1 (3) 1 (3) 
Histological grade 1 3 (10) 2 (6) 
2 10 (32) 17 (54) 
3 10 (32) 6 (20) 
Data not available 8 (26) 6 (20) 
Ki-67 ≥ 20% 9 (29) 20 (65) 
< 20% 9 (29) 9 (29) 
Data not available 13 (42) 2 (6) 
Hormonal receptor status 
(estrogen and progesterone) 
Both positive 18 (58) 21 (68) 
Only one positive 1 (3) 5 (16) 
Both negative 4 (13) 4 (13) 
Data not available 8 (26) 1 (3) 
c-erb2 Positive 3 (10) 11 (35) 
Negative 1 (3) –
Data not available 27 (87) 20 (65) 
Hormonal therapy Yes 18 (59) 21 (68) 
No 11 (35) 10 (32) 
Data not available 2 (6) 0 (0) 
Chemotherapy Yes 12 (39) 5 (16) 
No 17 (55) 24 (78) 
Data not available 2 (6) 2 (6) 
IBTR – ipsilateral breast tumor recurrence 
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dissection, and the median time to SBCS was 11.9 years 
(range, 2.5-27.8 years). The median dose of previous radi-
ation therapy was 60 Gy (range, 50-66 Gy). 
Ipsilateral breast tumor recurrence occurred at or 
near the same quadrant in 22 (71%) patients, while in 
9 (29%) patients was detected in a different quadrant of 
the breast. Primary tumor and locally IBTR showed the 
same histological type in 18 (58%) patients, while this in-
formation remained unknown for 2 patients (6.4%). 
Histological grade 3 was found in 10 (32%) and 6 (20%) 
patients with primary tumor and IBTR, respectively. 
A second surgical axillary staging was performed in only 
12 patients (39%). 
None of the BT implant was performed during a sur-
gical procedure; the median interval between salvage 
surgery and BT was 3.6 months (range, 1-8.2 months). 
The median number of catheters and planes was 9 
(range, 6-25 catheters) and 2 (range, 1-4 planes), respec-
tively. Dosimetric records were accessible for all, except 
for one patient. No technical problems, such as collaps-
es or kinking of flexible catheters allowing temporary or 
definitive breakdowns of treatment were recorded. Radi-
oprotection of staff was completed for each application. 
No complications involving the implant, such as bleeding 
or infection were noted. The procedure was well tolerat-
ed in all patients. None of the patients experienced severe 
pain or discomfort during treatment, and no BT-related 
infection was observed. 
Local control and survival rates
No patients were lost to follow-up. After a median 
follow-up of 73.7 months (range, 28.8-102.4 months), OS 
and CSS were 87.1% and 90.3%, respectively; 5-year LC 
and 5-year PFS were 90.3% and 83.9%, respectively. 
Further IBTR with or without concomitant regional 
and/or distant metastases occurred in 3 patients (9.7%) 
after 32, 39, and 44 months from SBCS: two of them 
were successfully salvaged with mastectomy, while 
a patient with concomitant distant metastasis received 
chemotherapy only. Two patients developed distant 
metastases. 
All but one of patients with a second relapse and/or 
metastasis had a Ki-67 ≥ 20% at first IBTR (4 out of 20 pa-
tients, 20%). Three of them had a histological G3 primary 
tumor (3 out of 10 patients, 30%) and developed the IBTR 
in a quadrant other than the initial primary cancer (3 out 
of 9 patients, 33%). 
Due to small number of patients, we did not find 
any other association between second relapse and tumor 
stage, histologic type, hormonal receptor status, or dosi-
metric parameters. 
Morbidity and cosmetic results 
No acute skin or soft tissue side effects higher than 
grade 2 were recorded, all were treated topically. All pa-
tients presented good cosmetic results (Figure 1). 
Fig. 1. A) Multicatheter interstitial implants; B) Follow-up 
at 1 month; C) Follow-up at 1 year 
C
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Probably, their unexpectedly positive judgment was 
intrinsically and psychologically influenced by the con-
servative result (even with a second surgery and a reirra-
diation) compared to the one they would have had if they 
had had to undergo a mastectomy. 
Most patients showed mild late side effects (grade ≤ 2), 
cutaneous and sub-cutaneous fibrosis (77.4%), retraction 
(24%), and telangiectasia (13.7%); only one patient de-
veloped grade 3 breast edema (Table 2). Asymptomatic 
fat necrosis was detected in one patient and required no 
surgical intervention. As stated by Wazer and colleagues, 
skin and subcutaneous toxicities (including fibrosis) are 
usually associated with the V150 and V200, and inversely 
associated with the dose homogeneity index (DHI): DHI 
= (V100 – V150)/V100, where V100, V150, and V200 are CTV 
volumes receiving 100%, 150%, and 200% of the pre-
scribed dose, respectively [63]. 
In the group of patients with grade 2 fibrosis and in 
the group with G0-G1 fibrosis, the median V150, V200, and 
DHI were 17.1 cm3 and 16.5 cm3, 7.5 cm3 and 7.6 cm3, and 
0.27 and 0.4, respectively. The patient with fat necrosis 
received a large BT implant with 18 catheters in 3 planes; 
her V150 and V200 were 59.9 cm3 and 30.2 cm3, respectively 
(Table 3). Late breast or chest wall pain of grade 2-3 were 
reported in 4 patients. No pleuritis, pneumonitis, pericar-
ditis, or rib fracture were observed. 
Discussion 
Local failure after breast conserving surgery and ra-
diotherapy represents a challenge for surgeons and ra-
diation oncologists to minimize morbidity while main-
taining optimal treatment outcomes. The importance of 
quality of life and body image require a mandatory at-
tention given to conservative surgical treatment of local 
recurrence. 
Compared to EBRT, the main advantages of BT, with 
the radiation sources directed on the tumor bed, include 
a higher localized dose around the target volume and 
a shorter overall treatment time. The rapid fall-off of doses 
around sources allows relative sparing of critical normal 
tissues. The main disadvantage of the partial breast reir-
radiation is the potential not-treatment of cancer occult 
foci in areas of the breast outside the implanted volume. 
Our analysis showed that adjuvant HDR-BT is a feasible 
treatment for recurrent breast cancer, offering low com-
plications rate and good cosmesis. At last follow-up, the 
OS and PFS were 87.1% and 83.9%, respectively, with LC 
of 90.3%. 
We have observed an increased risk of second relapse 
or metastasis in patients with a histological G3 primary 
tumor and/or an aggressive IBTR (Ki-67 ≥ 20%) devel-
oped in a quadrant other than the initial primary can-
cer. We were aware of the several limitations of a sin-
gle center retrospective analysis. Nevertheless, the data 
reported in this cohort showed excellent local control 
and survival rates, comparing very favorably with other 
published reports on HDR interstitial BT for treatment 
of IBTR with heterogeneous fractionation schemes and 
doses (Table 4). 
Niehoff et al. reported on 32 consecutive patients, who 
were affected by local recurrence after mastectomy (13 pa-
tients) or breast-conserving surgery (19 patients) and full-
dose adjuvant EBRT. Reirradiation was performed with 
HDR (15 patients; mean dose, 28 Gy; 2 × 2.5 Gy/day, with 
6 hours interfractional interval daily) or PDR-BT (17 pa-
tients; mean dose, 30 Gy; 5 × 1 Gy/day, with 2 hours of 
pulse intervals). After a mean follow-up of 19 months, lo-
cal control was achieved in 20 patients, but 20 of the 32 pa-
tients experienced an additional systemic progression [27]. 
Guix et al. reported on 36 patients with local recur-
rence after conservative treatment for breast cancer, treat-
ed by a second lumpectomy, and followed by adjuvant 
HDR-BT (30 Gy in 12 fractions in 5 days). Actuarial LC, 
DFS, and OS at 10 years were 89.4%, 64.4%, and 96.7%, 
respectively [32]. In 2011, the same group published an 
update on 85 patients with breast-only recurrence: 48 pa-
Table 2. Late toxicities (≥ 6 months after BT) observed during follow-up (n = 31 patients) 
Grade 0 Grade 1 Grade 2 Grade 3 
Edema 27 (87.1%) 3 (9.7%) 0 1 (3.2%) 
Fibrosis 7 (22.5%) 16 (51.6%) 8 (25.8%) 0 
Telangiectasia 26 (83.9%) 4 (12.9%) 1 (3.2%) 0 
Retraction 24 (77.4%) 5 (16.1%) 2 (6.4%) 0 
Skin atrophy 27 (87.1%) 4 (12.9%) 0 0
Table 3. Implant parameters (n = 30 patients) 
Median (range) 
Number of catheters 9 (6-25) 
Number of planes 2 (1-4) 
Volume of CTV 32.9 cm3 (9.1-143 cm3) 
V100 30.6 cm
3 (9.1-137 cm3) 
V150 16.5 cm
3 (7.8-101 cm3) 
V200 7.6 cm
3 (2.8-30.2 cm3) 
D90 41.4 Gy (27.5-53.4 Gy) 
DHI 0.4 (0.1-0.7) 
Treatment duration 6 days (5-8) 
CTV – clinical target volume, DHI – dose homogeneity index, D90 – dose to 90% 
of CTV, V100 – volume of CTV encompassed by 100% isodose, V150 – volume 
of CTV encompassed by 150% isodose, V200 – volume of CTV encompassed by 
200% isodose 
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Table 4. Overview of relevant publications on salvage BT 
Reference Number  
of patients 
Treatment modality Follow-up Clinical results 
Resch et al. [26] 17 8 pts, EBRT 12-30 Gy + 
PDR boost 12.5-28 Gy 
9 pts, PDR 40.2-50 Gy 
59 months 
(range, 20-84 months) 
LC, 70.5% 
Niehoff et al. [27] 32 
(13 patients post-mas-
tectomy) 
15 HDR, 
mean dose, 28 Gy 
17 PDR, 
mean dose, 30 Gy 
19 months LC, 20 pts 
M+, 32 pts 
Chadha et al. [28] 15 LDR, 
total dose, 30-45 Gy 
36 months 3-year OS, 100% 
MFS, 89% 
Trombetta et al. [29] 21 LDR, 
total dose, 45-55.3 Gy 
40 months 
(range, 3-69) 
LC, 95.2% 
OS, 90.4% 
Polgar et al. [30] 12 HDR, 
22 Gy; 5 fractions b.i.d. 
56 months 
(range, 8-112) 
MFS, 100% 
Adkinson et al. [31] 11 
(4 BCa; 6 HD; 1 STS) 
HDR, 
34 Gy; 10 fractions b.i.d. 
53.7 months LC, 100% 
OS, 100% 
Hannoun-Levi et al. [33] 42 HDR 
34 Gy; 10 fractions b.i.d. 
21 months LC, 97% 
Trombetta et al. [34] 18 
(16 BCa; 2 HD) 
HDR (balloon)
34 Gy; 10 fractions b.i.d.
39.6 months 
(range, 15-74) 
LC, 89% 
Kauer-Dorner et al. [35] 39 PDR,
mean total dose, 50.1 Gy
57 months 5-year LC, 93% 
5-year OS, 87% 
5-year DFS, 77% 
Guix et al. [36] 48 HDR 
30 Gy; 12 fractions b.i.d. 
– LC at 17 year, 84.2% 
DFS, 65.4% 
OS, 90.7% 
Hannoun-Levi et al.
GEC-ESTRO Breast Can-
cer working group [37] 
217 HDR (47%) 
PDR (40.6%) 
LDR (12.4%) 
46.8 months 
(range 13.2-123.6) 
5-year LC, 94.4% 
10-year LC, 92.8% 
5-year OS, 88.7% 
10-year OS, 76.4% 
5-year M+, 9.6% 
10-year M+, 19.1% 
Cozzi et al. [38] 40 HDR, 
32 Gy; 8 fractions b.i.d. 
34 Gy;10 fractions b.i.d. 
16 Gy; single fraction 
61.5 months 
(range, 6-153) 
5-year OS, 85.3% 
5-year LC, 96.6% 
5-year M+, 6% 
Smanyko et al. [39] 39 HDR, 
22 Gy; 5 fractions b.i.d. 
59 months 
(range, 1-189) 
5-year LC, 94% 
5-year DFS, 69% 
5-year OS, 81% 
Forster et al. [40] 19 HDR (58%) 
34.2 Gy; 9 fractions b.i.d. 
32 Gy; 8 fractions b.i.d. 
PDR (42%)
total dose, 49.8-50.4 Gy 
66 months 
(range, 18-120) 
5-year LC, 100% 
5-year DFS, 100% 
5-year OS, 100% 
Our study 31 HDR, 
34 Gy; 10 fractions b.i.d. 
73.7 months 
(range, 28.8-102.4) 
5-year LC, 90.3% 
5-year DFS, 83.9% 
5-year OS, 87.1% 
BCa – breast cancer, b.i.d. – bis in die, DFS – disease-free survival, GEC-ESTRO – Groupe Européen de Curiethérapie and European SocieTy for Radiotherapy and 
Oncology, HD – Hodgkin disease, HDR – high-dose-rate, LC – local control, LDR – low-dose-rate, MFS – mastectomy-free survival, M+ – systemic progression, 
OS – overall survival, PDR – pulsed-dose-rate, STS – soft tissue sarcoma 
tients were treated by a second lumpectomy followed by 
adjuvant HDR-BT, whereas 37 patients treated by mas-
tectomy had no further radiotherapy. Actuarial LC, DFS, 
and OS at 17-year were 84.2%, 71.7%, and 65.4% for SBCS, 
and 63.8%, 90.7%, and 88.2% for mastectomy, respective-
ly. Authors concluded that salvage lumpectomy and BT 
could be considered the treatment of choice in patients 
with recurrent breast tumors [36]. 
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Hannoun-Levi et al. presented clinical results of sec-
ond conservative treatment of combining surgery and 
HDR-BT (dose per fraction, 3.4 Gy; total dose, 34 Gy) 
in 42 patients affected by ipsilateral breast cancer recur-
rence. After a median follow-up of 21 months, second lo-
cal control rate was 97% with acceptable toxicity and high 
patient satisfaction regarding cosmetic results [33]. 
The Groupe Européen de Curiethérapie (GEC) and 
the European Society for Radiotherapy and Oncology 
(ESTRO) working group published a retrospective study 
on 217 patients treated with lumpectomy and multi-cath-
eter HDR (47%), PDR (40.6%), and LDR (12.4%) BT in 
8 institutions. After a median follow-up of 3.9 years (range, 
1.1-10.3 years), 5- and 10-year actuarial LC, OS, and distant 
metastasis rates were 94.4% (90.5-98.5%) and 92.8% (87.9-
87.9%), 88.7% and 76.4%, 9.6% and 19.1%, respectively, 
with excellent/good cosmetic result in 85% of cases [37]. 
Cozzi et al. evaluated a dataset of 40 patients treated 
with tumorectomy and interstitial intra- or post-opera-
tive HDR-BT with different schemes (32 Gy in 8 fractions; 
34 Gy in 10 fractions; 16 Gy in single fraction). Late fi-
brosis > grade 3 was observed in 14 patients (35%). The 
3- and 5-year OS was 97 and 85.3%, respectively. Local 
relapse and metastasis-free survival at 5 years were 96.6% 
and 94%, respectively [38]. 
More recently, Smanyko et al. reported clinical out-
comes of 195 patients with ipsilateral breast tumor recur-
rences treated with SBCS with interstitial BT (39 patients; 
dose per fraction, 4.4 Gy; total fractions, 5; total dose, 
22 Gy) or salvage mastectomy (156 patients). After a me-
dian follow-up of 6 years, a new local recurrence oc-
curred in 10.2% and 17.9%, and the 5-year disease-free 
survival was 69% and 65% in the conservative surgery 
+ BT group and in the mastectomy group, respectively. 
The 5-year probability of overall survival was 81% vs. 
66%, respectively [39]. 
Forster et al. analyzed results of 19 consecutive pa-
tients with small, low-risk breast recurrence (rpT1 cN0 
cM0, Her2 negative, preferably positive hormone recep-
tor status), treated with SBCS and interstitial multicath-
eter BT (8 PDR, 11 HDR). After a median follow-up of 
65 months, 5-year DFS and OS rates were both 100%; 
only one patient had a second in-breast recurrence at 
77 months after salvage treatment [40]. 
Comparable results were showed in smaller BT pa-
tient cohorts [26,30,31,34] and in patients treated with 
other types of adjuvant irradiation. SBCS and IORT 
presented LC and OS of 91-100% and 82-94%, respec-
tively [41,42,43,44,45,46], whereas a second EBRT after 
SBCS provided LC of 76.9-100% and OS of 62.5-100% 
[49,50,51,52,53]. 
Conclusions 
Despite small sample size, our preliminary results are 
comparable with literature data related to good feasibility 
of the technique, low toxicity profile, good tumor control, 
and encouraging cosmetic results. A close interdisciplin-
ary collaboration between the surgical and radiation 
oncology communities is required to individualize each 
treatment and to maximize patient care. 
Accelerated partial breast reirradiation using HDR-
BT offers an alternative to mastectomy in carefully select-
ed patients with a favorable breast recurrence. Further 
clinical trials are needed to identify possible subgroups of 
patients that might be suitable for this type of approach. 
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